Skip Navigation



Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Cardiology/Vascular Diseases | Endocrinology | Family Medicine

View By:YearCompanyConditionsTherapeutic AreasDrug Names

Teveten (eprosartan mesylate)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Company: SmithKline Beecham
Approval Status: Approved December 1997
Treatment Area: hypertension

General Information

Teveten was approved for the treatment of hypertension, as either a monotherapy or for use in combination with other antihypertensives.

Mechanism of Action

Teveten is an angiotensin II antagonist.